Becton Dickinson and Company
$ 180.62
5.21%
11 Feb - close price
- Market Cap 48,913,019,000 USD
- Current Price $ 180.62
- High / Low $ 182.00 / 170.67
- Stock P/E 33.93
- Book Value 88.53
- EPS 5.06
- Next Earning Report 2026-04-29
- Dividend Per Share $4.17
- Dividend Yield 2.56 %
- Next Dividend Date 2026-03-31
- ROA 0.04 %
- ROE 0.07 %
- 52 Week High 231.40
- 52 Week Low 157.52
About
Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.
Analyst Target Price
$197.54
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-03 | 2025-11-06 | 2025-08-07 | 2025-05-01 | 2025-02-05 | 2024-11-07 | 2024-08-01 | 2024-05-02 | 2024-02-01 | 2023-11-09 | 2023-08-03 | 2023-05-04 |
| Reported EPS | 2.91 | 3.96 | 3.68 | 3.35 | 3.43 | 3.81 | 3.5 | 3.17 | 2.68 | 3.42 | 2.96 | 2.86 |
| Estimated EPS | 3.24 | 3.92 | 3.4 | 3.28 | 2.99 | 3.77 | 3.31 | 2.97 | 2.4 | 3.43 | 2.91 | 2.74 |
| Surprise | -0.33 | 0.04 | 0.28 | 0.07 | 0.44 | 0.04 | 0.19 | 0.2 | 0.28 | -0.01 | 0.05 | 0.12 |
| Surprise Percentage | -10.1852% | 1.0204% | 8.2353% | 2.1341% | 14.7157% | 1.061% | 5.7402% | 6.734% | 11.6667% | -0.2915% | 1.7182% | 4.3796% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-29 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 3.33 |
| Currency | USD |
Previous Dividend Records
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-28 | 2024-03-29 | 2023-12-29 |
| Amount | $1.05 | $1.05 | $1.04 | $1.04 | $1.04 | $1.04 | $0.95 | $0.95 | $0.95 | $0.95 |
Next Dividend Records
| Dividend per share (year): | $4.17 |
| Dividend Yield | 2.56% |
| Next Dividend Date | 2026-03-31 |
| Ex-Dividend Date | 2026-03-10 |
Recent News: BDX
2026-02-11 23:28:32
Enovis (ENOV) is attracting renewed attention due to its presentation at the Annual MedTech conference, despite a challenging prior year with significant share price decline. Analysts view the stock as undervalued, with a fair value of $45.09 against a current price of $22.80, based on expected operational improvements and earnings growth. However, this positive outlook depends on successful integration of acquisitions and timely tech launches, with potential risks if delays occur.
2026-02-11 20:58:28
Embecta Corp. has announced the appointment of Devdatt Kurdikar as Chairman of the Board and Dr. Claire Pomeroy as Lead Independent Director. These changes follow the retirement of former Non-Executive Chairman, LTG (Ret.) David F. Melcher. Both Kurdikar and Pomeroy expressed confidence in leading embecta's transformation into a broader medical supplies company.
2026-02-11 18:26:23
Becton, Dickinson and Company (BD) completed the spin-off of its Biosciences & Diagnostic business, merging it with Waters Corporation, a move that aligns with BD's 2025 strategy to become a more focused MedTech organization. BD shareholders received Waters common stock, and BD gained $4 billion in proceeds, which it plans to use for share repurchases and debt reduction. The company aims to capitalize on trends like connected and AI-enabled medical technologies, strengthening its strategic focus and growth prospects.
2026-02-11 13:58:24
Becton, Dickinson and Company (BDX) has underperformed the broader market and healthcare sector ETFs over the past year. Despite beating Q4 2025 revenue and EPS estimates, the stock dropped due to a significant miss in life sciences revenue. Analysts currently hold a "Moderate Buy" consensus, with a mean price target suggesting an 18.8% upside.
2026-02-11 12:57:08
Madison Asset Management LLC reduced its stake in Waters Corporation (NYSE:WAT) by 1.5% in the third quarter, while institutional ownership remains high at 94.01%. Despite beating Q4 earnings estimates, Waters experienced share weakness due to Q1 2026 guidance falling below street expectations. Analysts hold a "Moderate Buy" rating, with an average target price of $400.84, although some firms adjusted targets due to integration risks with BD’s Biosciences & Diagnostic Solutions.
2026-02-11 12:16:08
Worldwide Market Reports has published a comprehensive study on the "Gram Staining Systems Market Size and Forecast 2026-2033," analyzing growth drivers, opportunities, restraints, and challenges. The report utilizes primary and secondary research, including SWOT analysis and Porter's Five Forces, to provide insights into market dynamics, competitive landscapes, and regional performance. It covers detailed market segmentation, key players like Thermo Fisher Scientific and Merck KGaA, and growth forecasts across various regions and applications.
